Log in

FYB Formycon AG XETR · Germany

Formycon (FYB) news

Formycon AG is a public biotech or pharmaceutical company listed on XETR under the ticker FYB, recorded under Germany. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Formycon news

We have not published a story on Formycon yet. When there is news, it will appear here.

Questions about Formycon

What is the ticker symbol of Formycon?

Formycon AG trades under the ticker FYB on XETR.

Where is Formycon listed?

Formycon AG is listed on XETR. Our directory also records these other listings: DUS:FYB; FWB:FYB; GETTEX:FYB; HAM:FYB; HAN:FYB; LS:A1EWVY; LSE:0W4N; LSX:A1EWVY; MUN:FYB; SWB:FYB; TRADEGATE:FYB; VIE:FYB.

Which country or territory is Formycon listed under?

Our directory records Formycon AG under Germany.

What does Formycon do?

Our directory classifies Formycon AG as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Formycon?

The ISIN recorded for Formycon AG is DE000A1EWVY8.

Does aibio.space cover Formycon?

aibio.space lists Formycon AG among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Formycon?

Companies in our directory listed in the same country and business area as Formycon: Immatics, Biofrontera, Merck KGaA, Heidelberg Pharma, Dermapharm Holding, Pentixapharm Holding.

Investor discussion: Formycon

Members talk about Formycon (FYB). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open XETR:FYB on TradingView.

Listing details

Formycon AG is a public biotech or pharmaceutical company listed on XETR under the ticker FYB, recorded under Germany. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Formycon AG
Ticker
FYB
Listing
XETR
Country or territory
Germany
Business scope
Pharmaceuticals: Major
ISIN
DE000A1EWVY8
Other listed symbols
DUS:FYB; FWB:FYB; GETTEX:FYB; HAM:FYB; HAN:FYB; LS:A1EWVY; LSE:0W4N; LSX:A1EWVY; MUN:FYB; SWB:FYB; TRADEGATE:FYB; VIE:FYB
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.